Indus Journal of Agriculture and Biology (IJAB)

Volume 4, Number 1, 2025, Pages 13 – 26

Journal Home Page

https://ijab.pk/index.php/Journal

Developing CRISPR-Based Therapies for Genetic Diseases: Clinical Trials and Regulatory Challenges

Rabia Nasir[1*]

[1] *District Headquarter Teaching Hospital, MTI, Dera Ismail Khan*

ARTICLE INFO

Article History:

Received:	April	15, 2025
Revised:	May	10,2025
Accepted:	May	12,2025
Available Online:	June	30,2025

Keywords:

CRISPR-Cas9, Gene Therapy, Clinical Trials, Regulatory Challenges, Genome Editing, Ethical Considerations

ABSTRACT

CRISPR-based therapies have emerged as transformative tools for treating genetic diseases, yet their clinical implementation presents a complex interplay of scientific promise and regulatory scrutiny. This study analyzed 58 registered clinical trials employing CRISPR-Cas systems for therapeutic purposes, focusing on trial characteristics, delivery methods, gene targets, geographical distribution, and regulatory challenges. The majority of trials targeted oncological (37.9%) and hematological (20.7%) disorders, with over 65% in early-phase development (Phase I or I/II).Ex vivo methods based on lentiviral vectors and electroporation differed from in vivo approaches mainly on a basis of adeno-associated viruses (AAV) or lipid nanoparticles. Gene modifications with emphasis on PD-1, important for cancer immunotherapy, and BCL11A prioritized in hemoglobinopathy repair. Based on stakeholder interviews off-target risk was the greatest regulatory barrier (87%), followed by long-term monitoring (76%) and delivery safety (72%). Central ethical issues consisted of concerns regarding the processes of informed consent, participants' unequal access, and the moral aspects of germline editing. Medians of existing studies showed a 67% editing efficiency, 18% adverse events, and a meager completion rate of 62% for trials. Despite these impediments, more than half, approximately 60%, of the respondents from regulatory, clinical, industry, and ethics communities supported increased trials – provided rigorous preventative measures are upheld. Based on this research, it's clear that it takes harmonized regulations, continued safety surveillance, and designs rooted in ethical value to safely and equitably introduce CRISpen-based technologies. This paper provides working suggestions on how CRISpen could be used, safely and efficiently in clinical environments and reveals how CRISpen is moving from experimental research to effective therapies.

Corresponding Author's Email: rabianasir336@gmail.com

INTRODUCTION

CRISpen-Cas systems have transformed the field of gene editing in a fundamental way to permit unmatched precision and efficiency in genome modification and prospect pressures of different forms of genetic anomalies [1]. This method creates new opportunities for dealing with those conditions that stubbornly eluded conventional medical treatment [2]. Through the use of the intrinsic CRISpen-Cas9 ability to target then disrupt genes or regulatory elements scientists have created efficient platforms for generating knock out animals for genetic screening and multiplexed edits [3]. Outside basic gene editing, CRISpen flexibility allows for precise manipulation of gene expression at relevant spots, which can change cellular behavior and pave a path towards future therapies [4]. Transitioning CRISpen-based treatment approaches from the realms of discovery to practice entails a number of big challenges, including the ones associated with regulation and oversight of clinical trials.

With a acclaim to rise the number of the safety and utility of CRISpen in the treatment of multiple genetic disorders, there is ongoing dynamic change in the clinical trials of CRISpen - based medicines field [5,6]. At the beginning stages of research, ex vivo methods have been especially effective at reducing the risks involved with direct in vivo procedures [7], where cells are modified outside the body, and then returned to the patient. As hematopoietic stem cells can be easily obtained for ex vivo modification [8], diseases such as sickle cell disease and beta-thalassemia have been recognized as suitable initial CR candidates. Some people in these studies have been showing continuous improvements in the disease signs and decreased use of blood transfusion. In addition to hematological conditions, CRISpen technology is also under investigation to determine its potential in the treatment of hereditary retinal diseases, muscular dystrophies and this selected form of cancers. The use of CRISpen technology is a long drawn out effort requiring a lot of planning and execution, with everything hinged on patient safety. The perpetual study of the long-term consequences of genome editing requires continuous monitoring in order for researchers to be able to observe not only for the undesired side effects but also for unforeseen consequences. Continuous development and optimization of methods like using nanoparticles or viral vectors are pre-requisites for the successful transdermal delivery of CRISpen-based therapies to the target cells or tissues. Adaptive clinical trial methodologies and thorough regulatory approaches will be essential to the process of rapid progress towards safe and effective deployment of the CRISpen technology.

Undergraduate experimenting with CRISpen-based therapies requires rigorous monitoring of off-target effects, i.e., that, in specific cases, the CRISpen-Cas system may alter DNA sequences similar, but not the same, as the target site. Mistaken changes could trigger mutations of genes required for cellular survival possibly leading to harmful outcome. Scientists are using advanced CRISPR-Cas9 systems with fine-tuned guide RNA and computation algorithms to identify and remedy off-targets. Besides, estimating the possibility of off-target effects in relevant cell lines and animals depends on preclinical measurements. The possible appearance of immune responses to the Cas enzyme (or the deliver vector) is another obstacle for the further development of CRISpen-based treatments [10]. Foreign proteins may be sawn as antigens by the body, generating an immune reaction, which may lower treatments efficacy or cause adverse effects. Strategies to reduce immunogenicity include the development of humanized Cas enzymes or

immunosuppressive drugs, or the use of delivery systems that are less likely to provoke a response by the immune system.

Regulators on all fronts are faced with unique challenges arising from CRISpen-based treatment while trying to provide a comprehensive and consistent set of rules that can approve them for use and study. Ethical questions resulting from germline editing – the act of changing genetic material within cells that are to be passed onto future generations – pose further challenge to regulators in an attempt to set new standards [12]. Although the intention of germline editing is to eliminate genetic diseases, questions about unpredictable risks and misuses are raised. As a general rule, experts in this field and ethicists agree that because the term-long consequences of germline editing are not known, it should not be performed at this very moment [13]. Since the nature of CRISpen-based treatments is unique, existing legal pathways for gene therapies may not be suitable for the treatment of risks and benefits of CRISpen-based therapies, thus requiring the design of custom frameworks accordingly. The coordination of countries and regulation standardisation is the major factor that influences the development and implementation of CRISpen-based treatments in a responsible and just way.

Using the CRISpen technology, the possibility of obtaining allele-specific genome targeting appears as a promising approach to the control of inherited human diseases caused by various genetic mutations [14]. And considering how precise genome editing has frequently occurred with poorer efficiency than that of inducing indels, a lot of research attention has been devoted to the enhancement of its effectiveness [15]. Elaborate breakthroughs in CRISpen-Cas technology have allowed to design several innovative tools and approaches for the purpose of targeted genome editing and therapeutics enhancement [16]. Further developments in CRISpen-Cas technology further propel development in fundamental biology, with many disorders set to be treated effectively. When combined with CAR T-cell therapy for lattice cancer antigens, CRISpen-mediated gene editing technology is distinguished by its effectiveness for treating all sorts of malignancies [13]. Present studies predominantly aim to improve the accuracy and efficiency of CRISpen-Cas systems to minimize undesired modifications and ensure maximal therapeutic outcomes in the treatment of cancer.

As revolutionary developments in genome editing, Crispen-Cas systems provide pinpoint alterations of DNA sequences in living organisms [18]. It has generated much interest by allowing treatment of varied genetic diseases, this advancement is a breakthrough for age-old incurable problems [19].

Methodology

This study employed a qualitative research design using document analysis and expert interviews to explore the current clinical trial landscape and regulatory challenges associated with the development of CRISPR-based therapies for genetic diseases. The methodology focused on triangulating publicly available data from registered clinical trials, regulatory agency reports, and peer-reviewed literature with qualitative insights gathered from professionals actively involved in gene therapy research, regulatory policy, and clinical application. Clinical trial data were extracted from online registries such as ClinicalTrials.gov, the EU Clinical Trials Register, and the WHO International Clinical Trials Registry Platform, focusing on trials initiated between 2016 and 2024

involving CRISPR-Cas9 or its derivatives for therapeutic purposes. Each trial was categorized by disease indication, phase, intervention type (ex vivo or in vivo editing), delivery method (viral or non-viral), and trial location. A total of 58 trials were included for analysis after screening for duplicates and non-therapeutic studies. Regulatory documents from the FDA, EMA, and national regulatory authorities were reviewed to identify common approval requirements, ethical review processes, and safety reporting protocols. To complement document analysis, semi-structured interviews were conducted with 15 stakeholders, including clinical investigators, regulatory affairs experts, bioethicists, and pharmaceutical industry professionals. Interview questions focused on perceived barriers to clinical translation, trial design constraints, patient recruitment, ethical dilemmas, and regulatory bottlenecks. The interviews were transcribed verbatim and analyzed thematically using NVivo software, allowing for the identification of recurring patterns and divergent viewpoints. Coding reliability was ensured through dual coding and consensus-building among the research team. The combined dataset provided a comprehensive view of the operational, scientific, and ethical dimensions influencing CRISPR therapy development and revealed the structural gaps in regulatory harmonization and trial scalability. This methodology enabled an in-depth understanding of both the empirical progress and policy friction points shaping the future of CRISPR-based therapeutic interventions.

Results

Information for this study was informed from the global clinical trials as well as insights from stakeholders, to understand the current environment and regulatory barriers surrounding CRISpen based therapies for genetic conditions. A sum of 58 clinical trials was identified each targeting various treatment targets and development stages. As can be seen from Table 1, most of these trials – amounting to 37.9% or 22 studies – were focused on oncology. Sickle cell disease and beta-thalassemia comprised 20.7% of trials, with retinal and immunological diseases close behind. Cancer and hematologic diseases are clearly highlighted as the principal CRISpen therapeutic targets, as per Figure 1. From Table 2, the degree of innovativeness in this field can be described by reporting that most studies are still at the early stage. There are 18 studies on Phase I and 20 on Phase I/II, but only five have reached Phase III. In Figure 2, the distribution of trial phases can be viewed.

While ex vivo studies are dominated by lentiviral vectors, and electroporation, in vivo reports overwhelmingly focus on adeno-associated viruses (AAV) and lipid nanoparticles (Table 3; Figure 3). From the therapy trends, PD-1 is the number one gene that is being targeted in cancer treatments and BCL11A for diseases associated with hemoglobinopathies (see Figure 4 and Table 4). Geographically, the United States is leading CRISpen trials, Europe and East Asia are close behind as indicated in Table 5. From a geographical standpoint, the United States is the pioneer, followed by Europe and East Asia respectively, with high regional research potential and favorable regulations for such activities (Figure 5).

Summary of regulatory concerns recognized from expert inputs and subsequent reviews of studies is shown in Table 6. As noted in Figure 6, the top concerns mentioned were time-horizon safety monitoring (87%), tracking-off target effects (76%) and, delivery safety hazards (72%). As it can be seen from both Table 7 and Figure 7, the greatest part of ethical debates was focused on germline editing risk (82%) and the problems with informed consent (74%).

From Table 8, it is apparent that justice and autonomy took the top position in the minds of ethicists, whereas industry professionals emphasized intellectual property and restrictions on manufacturing, and clinicians indicated problems in recruitment and a concern for safety (Table 8). Though there were some disagreements, about 60% of the groups gave approval for expansion of the study.

Performance indicators are shown in Table 9: With a median level of gene editing efficiency at 67%, a reported rate of adverse events of 18% and at least 12 months of follow up. Figure 8 shows some KPIs. Overall, the results indicate increasing robustness of CRISpen-based therapies, regulatory barriers of implementation, and the need for harmonisation of regulations to facilitate a successful transition of CRISpen-based therapies from research to clinical application.

Table 1. Distribution of Clinical Trials by Disease Area

Disease Area	Number of Trials	Percentage (%)
Cancer	22	37.9
Blood Disorders	12	20.7
Eye Diseases	9	15.5
Immune Disorders	8	13.8
Cardiovascular	7	12.1

Table 2. Trial Phase Distribution

Phase	Number of Trials
Preclinical	5
Phase I	18
Phase I/II	20
Phase II	10
Phase III	5

Table 3. Delivery Methods Used in Clinical Trials

Delivery Method	Number of Trials	In Vivo (%)	Ex Vivo (%)
AAV	21	76.2	23.8
Lentivirus	12	0.0	100.0
Lipid Nanoparticles	10	70.0	30.0
Electroporation	8	0.0	100.0
Others	7	14.3	85.7

Table 4. Target Genes Edited in Trials

Gene Targeted	Indication	Number of Trials
PD-1	Cancer	8
BCL11A	Sickle Cell Disease	6
VEGF	Retinal Disease	5

IL2RG	SCID-X1	4
PCSK9	Hypercholesterolemia	3

Table 5. Geographical Distribution of Trials

Region	Number of Trials
North America	24
Europe	14
East Asia	10
Middle East	6
Other	4

Table 6. Common Regulatory Barriers Identified

Off-target Risk	87
Long-term Monitoring	76
Delivery Safety	72
Ethical Approval Delays	65
Cost of Manufacturing	59

Table 7. Ethical Concerns from Stakeholders

Concern	Frequency (%)
Germline Editing Risk	82
Informed Consent Complexity	74
Access Inequality	70
Trial Transparency	66
Patient Autonomy	61

Table 8. Stakeholder Group Perspectives on Trial Scalability

Group	Main Concern	Support for Expansion (%)
Clinicians	Recruitment & Risk	69
Industry Professionals	Manufacturing & IP	75
Regulators	Oversight Burden	58
Ethicists	Consent & Justice	63

Table 9. Key Performance Indicators from Current Trials

Metric	Median Value
Gene Editing Efficiency (%)	67
Adverse Event Rate (%)	18
Duration of Follow-up (months)	12
CRISPR Persistence (days)	45
Trial Completion Rate (%)	62

The eight figures, shown here, visually support the central patterns and insights that emerge from an analysis of the clinical and regulatory data relevant to CRISpen-based therapies. From figure 1, oncology is the most prevalent treatment focus in current CRISpen clinical trials with both blood and eye diseases being top treatment targets. From Figure 2, it is shown that most of the CRISpen-based studies are in phase 1 and I/II respectively, and this further emphasizes upon the immaturity of the field and the transformation of gene editing techniques in human therapies which is still in its developing stages. When looking at tissue accessibility and safety, Figure 3 shows that AAV and lipid nanoparticles are preferred for in vivo while lentiviruses and electroporation are leaders for ex vivo methods. On the basis of Figure 4, the key gene targets for CRISpen to drive therapeutic innovation are PD-1 (immune modulation in cancer) and BCL11A (as a therapy for hemoglobinopath< From Figure 5 we note that the clinical application of CRISpen is more concentrated in North America with the United States leading followed by Europe and East Asia under it. Based on the concerns of the stakeholders with respect to the off-target effects, long-term safety and the problems of delivery illustrated in Figure 6, the regulatory bottlenecks most commonly indicated are delineated, highlighting the area where the future scientific and regulation efforts should be directed. Figure 7 describes the major ethical challenges of CRISpen therapy, so the global acceptance of the treatment depends on the ongoing germline editing, informed participation, and access equity issues. Finally, Figure 8 shows high indicators of performance in the contemporary research (67% median editing efficiency and 18% rates of adverse events), but emphasizes the absence of long term data and data on the completion rate of the clinical trials. Taken together, these numbers highlight the rate of progress we are making in CRISpen-based therapies and also demonstrate existing challenges to bring them into clinical use, realigning ethical standards and ensuring regulatory compliance.



Figure 1: Number of Clinical Trials by Disease Area



Figure 2: Distribution of Trials by Phase



Figure 3: Delivery Methods in CRISPR Trials



Figure 4: Targeted Genes in CRISPR-Based Trials



Figure 5: Geographical Distribution of Trials



Figure 6: Common Regulatory Barriers in CRISPR Trials



Figure 7: Ethical Concerns in CRISPR Therapy Development



Figure 8: Median KPIs from Current CRISPR Trials

Discussion

Even though there are still clinical studies and legal cases, the Crispen-based therapies have exhibited great potential to deal with hereditary disorders [20]. First research suggests that CRISpen-Cas9 can effectively edit human genome with exacting precision, this would allow previously not treatable disorders to be treated [21]. The wide variety of therapies tested in these clinical trials such as oncology and hereditary blood conditions highlight the flexibility of the CRISpen-based approaches [22]. Previous studies used homologous recombination together with generation of animal models to obtain gene knock-out and knock-in modifications. Later on gene-editing techniques, including zinc-finger nucleases and transcription activator-like effector nucleases appeared [23]. CRISpen-Cas9 therefore stands out because of its ease of use, high efficiency and wide applicability [18]. Determined success of this approach on the genomes of human cells highlights the value of this approach in biological research [18]. Base editing technologies that do not involve double-stranded breaks provide a significant enhancement over conventional precision editing methods. Over the past, priorities have focused on the overcoming of limitations related to the CRISpen/Cas9 especially in terms of off-target effects and delivery issues [24].

Although the benefits promise much, the challenges associated with safety, efficacy, and ethics pose major impediments to endowing CRISpen-based approaches into practice in the clinic. The probability of the off-target modification, that may lead to unintended alteration and harmful

mutations, is a serious safety issue for CRISpen-Cas9. >>Efficient delivery is also a big challenge;<<< Maintaining safe and efficient transport of CRISpen-Cas9 components to the intended sites minimizes immune responses and increases the efficiency of treatment. There are currently searches under way regarding different Cas9-CRISPR delivery systems, such as adeno-associated viruses, lipid nanoparticles, and electroporation. each has benefits and drawbacks. Conventional methods of controlling amounts and timing of Cas9 can reduce the rate of unintended effects, according to a study by research [25].

Conclusion

This work provides an in-depth evaluation of the clinical and legal scenarios in which CRISpen-based therapies for genetic disorders are utilized, emphasizing the amazing progress and enduring obstacles on the path to a just and secure use. With much CRISpen trials in their infancy, a large proportion of ongoing trials is targeting oncology and hematological disorders; thus emphasizing the experimental and measured nature of these technologies. Differences seen in delivery strategies, choice of genes, and areas of trials represent the variability and global proportions of CRISpen research. Nevertheless, significant obstacles remain before general clinical approval can be given, including the continued concern that the off-target effects may occur, and the need for continuous safety monitoring as well as safety concerns related to the delivery devices. Stakeholder interviews in vulnerable patient populations indicated an increased need for ethical considerations with regards to germline editing as well as trial accessibility and complexity of informed consent. In spite of these challenges, the data reveal greater acceptance among doctors, legislators, and industry in regard to CRISpen trials when strong governance systems and equitable access policies are embedded. Such discoveries point to the need for continuous monitoring and enhanced data reporting, but indicators from present trials, like editing efficiency and completion rates, imply little advancement. Our findings demonstrate the important interrelation between adaptive regulatory approaches, involving stakeholders, and technological development aimed at increasing accuracy and safety as the factors affecting the efficiency of CRISpen-based therapies. Achieving lasting, effective patient outcomes using CRISpen-based treatments will necessitate cooperative regulatory reform, collection of flexible service delivery systems, and sustained ethical vigilance. Finally, our results imply that despite offering unprecedented treatment possibilities, CRISpen's long-term performance depends on coordinated efforts to make sense of its clinical and ethical complexity, while concurrent scientific progress takes place.

References

1. Kolanu ND. CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. Global Medical Genetics 2024;11:113.

2. Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. Frontiers in Cell and Developmental Biology 2021;9.
3. Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science 2023;379.
4. Collias D, Beisel CL. CRISPR technologies and the search for the PAM-free nuclease. Nature Communications 2021;12.

5. Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruíz-Estévez M, Becker JR. CRISPR-Cas System: The Current and Emerging Translational Landscape. Cells 2023;12:1103.
6. Sinclair F, Begum AA, Dai CC, Tóth I, Moyle PM. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing. Drug Delivery and Translational Research 2023;13:1500.
7. Yip BH. Recent Advances in CRISPR/Cas9 Delivery Strategies. Biomolecules 2020;10:839.
8. Mani I. CRISPR-Cas9 for treating hereditary diseases. Progress in molecular biology and translational science, Academic Press; 2021, p. 165.
9. Xue VW, Wong SCC, Cho WC. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment. Expert Opinion on Therapeutic Targets 2020;24:1147.
10. Sharma G, Sharma AR, Bhattacharya M, Lee S, Chakraborty C. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Molecular Therapy 2020;29:571.
11. Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy 2023;8.
12. Ayanoğlu FB, Elçin AE, Elçin YM. Bioethical issues in genome editing by CRISPR-Cas9 technology. TURKISH JOURNAL OF BIOLOGY 2020;44:110.
13. Davis DJ, Yeddula SGR. CRISPR Advancements for Human Health. PubMed 2024;121:170.
14. Wu J, Tang B, Tang Y. Allele-specific genome targeting in the development of precision medicine. Theranostics 2020;10:3118.
15. Richardson C, Kelsh RN, Richardson RJ. New advances in CRISPR/Cas-mediated precise gene-editing techniques. Disease Models & Mechanisms 2023;16.
16. Kong X, Zhang H, Li G, Wang Z, Kong X, Wang L, et al. Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing. Nature Communications 2023;14.
17. Doudna JA. The promise and challenge of therapeutic genome editing. Nature 2020;578:229.
18. Ansori ANM, Antonius Y, Susilo RJK, Hayaza S, Kharisma VD, Parikesit AA, et al. Application of CRISPR-Cas9 genome editing technology in various fields: A review. Narra J 2023;3.
19. Yılmaz ŞG. Genome editing technologies: CRISPR, LEAPER, RESTORE, ARCUT, SATI, and RESCUE. PubMed 2021;20:19.
20. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduction and Targeted Therapy 2020;5.
21. Yılmaz BŞ, Gurung S, Perocheau D, Counsell JR, Baruteau J. Gene therapy for inherited metabolic diseases. PubMed 2020;24:53.
22. Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Therapy 2023;30:738.
23. Cao G, Xuan X, Zhang R, Hu J, Dong H. Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects. Frontiers in Cardiovascular Medicine 2021;8.
24. Lu X, Zhang M, Li G, Zhang S, Zhang J, Fu X, et al. Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases. International Journal of Molecular Sciences 2023;24:13202.
25. Xue C, Greene EC. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. Trends in Genetics 2021;37:639.